The Biden administration has a 'timely plan for J&J booster shots,' too, surgeon general says

Johnson & Johnson vaccine
(Image credit: Patrick T. Fallon/AFP/Getty Images)

Federal health officials on Wednesday advised the more than 150 million Americans who've gotten two doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines that they should get a third shot starting Sept. 20.

But what about the 14 million who opted for the one-and-done Johnson & Johnson vaccine? "We anticipate vaccine boosters will likely be needed" for them, too, Surgeon General Vivek Murthy said at a White House briefing. "We expect more data on J&J in the coming weeks. With those data in hand, we will keep the public informed of a timely plan for J&J booster shots."

The Biden administration is pushing a booster shot because the mRNA vaccines, Pfizer and Moderna, appear to be losing some efficacy against the much more transmissible Delta variant. There's less data for the Johnson & Johnson shot's longevity, though Johnson & Johnson told The New York Times it will "will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine," probably "in the coming weeks."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.


Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

"If you're doing data-driven decisions and you don't have the data, what can you do?" asked John Moore, a virologist at Weill Cornell Medicine. He told the Times he "would be very, very surprised" if the U.S. didn't approve a second J&J shot "in the reasonably near future," adding, "The federal government is well aware of the J.&J. situation. ... It's not being overlooked."

Dr. Dan Barouch, a virologist at Boston's Beth Israel Deaconess Medical Center, said new real-world data from health workers in South Africa has "very clear results showing that the single-shot J&J vaccine provided substantial protection against the Delta variant." Barouch and Moore said they expect that when the booster shot is approved, it will be for a second J&J dose, not Pfizer or Moderna.

To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us